SMN1 and amyotrophic lateral sclerosis: Other diseases being targeted by this approach are SMA (Spinraza, ASO [12]; Evrysdi, small molecule [13]), amyotrophic lateral sclerosis (ALS) (Tofersen, ASO) [14], and DMD (Etepliersen, exon 51 skipping, ASO [15]; Golodirsen, exon 53 skipping, ASO [16]; Viltolarsen, exon 53 skipping, ASO [17]; and Casimersen, exon 45 skipping, ASO [18]).